Experienced in Thymectomy

Dr. Deepa Rangachari

Oncology
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
330 Brookline Ave, 
Boston, MA 
Accepting New Patients
Offers Telehealth
Experienced in Thymectomy
Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc
330 Brookline Ave, 
Boston, MA 
OverviewInsuranceLocationsClinical ResearchSimilar Doctors

Overview

Deepa Rangachari is an Oncologist in Boston, Massachusetts. Dr. Rangachari is rated as an Experienced provider by MediFind in Thymectomy. Her top areas of expertise are Lung Cancer, EGFR Positive Lung Cancer, Non-Small Cell Lung Cancer (NSCLC), Lung Adenocarcinoma, and Thymectomy. Dr. Rangachari is currently accepting new patients.

Her clinical research consists of co-authoring 84 peer reviewed articles and participating in 5 clinical trials. MediFind looks at clinical research from the past 15 years. In particular, she has co-authored 1 article in the study of Thymectomy.

Specialties
Oncology
Licenses
Internal Medicine in MD
Hospital Affiliations
Beth Israel Deaconess Hospital - Needham
Beth Israel Deaconess Medical Center
Languages Spoken
English
Gender
Female

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Anthem
  • EPO
  • HMO
  • POS
  • PPO
Blue Cross Blue Shield
  • EPO
  • HMO
  • POS
  • PPO
BMC HealthNet
  • HMO
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE SNP
Cigna
  • EPO
  • HMO
  • PPO
Commonwealth Care Alliance
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Managed Medicaid
  • OTHER MANAGED MEDICAID
Mass General Brigham Health Plan
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
Tufts
  • HMO
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 8 Less Insurance Carriers -

Locations

HARVARD MEDICAL FACULTY PHYS AT BETH ISRAEL DEACONESS MED CTR INC
330 Brookline Ave, Boston, MA 02215

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

5 Clinical Trials

Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Biomarkers of Response to Ipilimumab and Nivolumab as First-line Therapy for Metastatic Non-small Cell Lung Cancer (NSCLC): an Open-label, Single Arm Phase 2 Study
Enrollment Status: Terminated
Publish Date: September 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
LUNAR: Pivotal, Randomized, Open-label Study of Tumor Treating Fields (TTFields) Concurrent With Standard of Care Therapies for Treatment of Stage 4 Non-small Cell Lung Cancer (NSCLC) Following Platinum Failure
Enrollment Status: Completed
Publish Date: October 21, 2024
Intervention Type: Drug, Device
Study Drug: Immune checkpoint inhibitors or docetaxel
Study Phase: Phase 3
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Phase I/II Study of Olaparib and Temozolomide in Patients With Recurrent Small Cell Lung Cancer Following Failure of Prior Chemotherapy
Enrollment Status: Unknown
Publish Date: February 07, 2022
Intervention Type: Drug
Study Drugs: Olaparib, Temozolomide
Study Phase: Phase 1/Phase 2
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Phase 1b Study of LY3295668 Erbumine Monotherapy in Patients With Platinum-Sensitive, Extensive-Stage Small-Cell Lung Cancer
Enrollment Status: Completed
Publish Date: August 05, 2021
Intervention Type: Drug
Study Phase: Phase 1
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
An Open-label, Single-Arm, Phase 2 Study Evaluating the Efficacy, Safety and Pharmacokinetics of Rovalpituzumab Tesirine (SC16LD6.5) for Third-line and Later Treatment of Subjects With Relapsed or Refractory Delta-Like Protein 3-Expressing Small Cell Lung Cancer (TRINITY)
Enrollment Status: Completed
Publish Date: July 30, 2021
Intervention Type: Drug
Study Phase: Phase 2
View 4 Less Clinical Trials

84 Total Publications

Fortifying the Workforce: A National Survey of Hematology/Oncology Fellowship Program Leaders Regarding Training Fellows for Community-Based Careers.
Fortifying the Workforce: A National Survey of Hematology/Oncology Fellowship Program Leaders Regarding Training Fellows for Community-Based Careers.
Journal: JCO oncology practice
Published: August 01, 2025
Similar Doctors
Experienced in Thymectomy
Dr. Emily S. Gatof
Oncology
Experienced in Thymectomy
Dr. Emily S. Gatof
Oncology

Harvard Medical Faculty Phys At Beth Israel Deaconess Med Ctr Inc

330 Brookline Ave, 
Boston, MA 
 (0.1 miles away)
617-754-8612
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Emily Gatof is an Oncologist in Boston, Massachusetts. Dr. Gatof is rated as an Experienced provider by MediFind in Thymectomy. Her top areas of expertise are Lymphofollicular Hyperplasia, HER2 Negative Breast Cancer, BRCA Positive Breast Cancer, Thymic Epithelial Tumor, and Thymectomy.

Experienced in Thymectomy
Dr. David B. Sykes
Hematology | Oncology
Experienced in Thymectomy
Dr. David B. Sykes
Hematology | Oncology

Massachusetts General Physicians Organization Inc

55 Fruit St, 
Boston, MA 
 (2.5 miles away)
617-724-0287
Languages Spoken:
English
See accepted insurances
Accepting New Patients
Offers Telehealth

David Sykes is a Hematologist and an Oncologist in Boston, Massachusetts. Dr. Sykes is rated as a Distinguished provider by MediFind in Thymectomy. His top areas of expertise are Agranulocytosis, Chronic Familial Neutropenia, Polycythemia Vera, Bone Marrow Transplant, and Bone Marrow Aspiration. Dr. Sykes is currently accepting new patients.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Rangachari's expertise for a condition
ConditionClose
View All 8 Distinguished Conditions
View All 13 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile